Literature DB >> 6523531

The effect of five synthetic progestational compounds on 5 alpha-reductase activity in genital skin fibroblast monolayers.

H J Dean, J S Winter.   

Abstract

The suggestion has been made that prenatal exposure to synthetic progestogens contributes to an increased incidence of hypospadias. One potential mechanism for such an effect might be inhibition of 5 alpha-reductase, a key enzyme in normal male sexual differentiation. We have examined the effect of progesterone and of five synthetic progestogens upon 5 alpha-reductase activity in fibroblast monolayers from 12 genital skin cell lines obtained from normal newborn infants, boys with phimosis and hypospadias and a normal adult male. Basal enzyme activities ranged from 0.8-12.1 pmoles 5 alpha-reduced product/micrograms DNA/hour. Progesterone and norethindrone inhibited 5 alpha-reductase activity in a dose dependent manner to a maximum of 95% and 50% of basal levels respectively at 10(-5) M. Similar concentrations (10(-5) M) of norethynodrel, ethisterone, dl-norgestrel and d-norgestrel had little or no effect. Studies of cell viability showed that the effects of progesterone and norethindrone were specific for 5 alpha-reductase and not non-specific toxic effects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6523531     DOI: 10.1016/0039-128x(84)90055-2

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  2 in total

1.  Altered balance between the 5 alpha-reductase and aromatase pathways of androgen metabolism during controlled ovarian hyperstimulation with human menopausal gonadotropins.

Authors:  C C Slater; L Chang; F Z Stanczyk; R J Paulson
Journal:  J Assist Reprod Genet       Date:  2001-10       Impact factor: 3.412

2.  Dose-related estrogen effects on gene expression in fetal mouse prostate mesenchymal cells.

Authors:  Julia A Taylor; Catherine A Richter; Atsuko Suzuki; Hajime Watanabe; Taisen Iguchi; Kathryn R Coser; Toshihiro Shioda; Frederick S vom Saal
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.